021-51111890
购物车（）
sales@molnova.cn
AL-9
CAS No. 869218-90-6
AL-9 ( HCV inhibitor AL-9 )
产品货号. M16312 CAS No. 869218-90-6
AL-9 is a small molecule HCV replication inhibitor with EC50 of 0.29 and 0.75 uM for genotype 1b and 2a.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥7857 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称AL-9
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述AL-9 is a small molecule HCV replication inhibitor with EC50 of 0.29 and 0.75 uM for genotype 1b and 2a.
-
产品描述AL-9 is a small molecule HCV replication inhibitor with EC50 of 0.29 and 0.75 uM for genotype 1b and 2a, inhibits purified PI4KIIIα with IC50 of 0.57 uM; inhibits HCV across different genotypes with activity in the sub-micromolar to low micromolar range in the absence of significant cytotoxic effects; inhibits PI4KIIIα also in living cells, while not appreciably affecting the activity of PI4KIIIβ, does not affect the level of PI4P in the Golgi membrane.
-
同义词HCV inhibitor AL-9
-
通路Microbiology/Virology
-
靶点HCV
-
受体HCV
-
研究领域——
-
适应症——
化学信息
-
CAS Number869218-90-6
-
分子量402.45
-
分子式C23H22N4O3
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESOCC1=CC=C(C2=CC3=C(NC4=CC=C(N5CCOCC5)C=C4)N=CN=C3C=C2)O1
-
化学全称(5-(4-((4-morpholinophenyl)amino)quinazolin-6-yl)furan-2-yl)methanol
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Bianco A, et al. PLoS Pathog. 2012;8(3):e1002576.
2. MacLeod AM, et al. ACS Med Chem Lett. 2013 May 8;4(7):585-9.
2. MacLeod AM, et al. ACS Med Chem Lett. 2013 May 8;4(7):585-9.
产品手册
关联产品
-
Filibuvir
Filibuvir (PF-00868554;PF-868554) is a nonnucleoside, potent and selective, orally available HCV NS5B inhibitor with IC50 of 19 nM, EC50 of 75 nM.
-
Glecaprevir
Glecaprevir (ABT 493;A 1282576) is a novel HCV NS3/4A protease inhibitor with pan-genotypic activity, inhibits NS3/4A proteases from HCV genotypes 1-6 in vitro with IC50 of 3.5-11.3 nM.
-
R-7128
The prodrug of PSI-6130, a potent, specific inhibitor of HCV RNA synthesis by inhibiting the NS5B RNA polymerase.
